Glucagon challenge in the rat: A robust method for the in vivo assessment of Glycogen phosphorlyase inhibitor efficacy

Journal of Pharmacological and Toxicological Methods

Volumn 55, Issue 1, 2007, Pages 71-77

  Loxham, Susan J G ^a   Teague, Joanne ^a   Poucher, Simon M ^a   De Schoolmeester, Joanne ^a   Turnbull, Andrew V ^a   Carey, Frank ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Glucagon; Glycogen phosphorylase; Methods; Wistar rat; Zucker rat

Indexed keywords

1,4 DIDEOXY 1,4 IMINO DEXTRO ARABINITOL; ENZYME INHIBITOR; GLUCAGON; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITOR 296; N [1 BENZYL 3 (3,4 DIHYDROXYPYRROLIDIN 1 YL) 2 HYDROXY 3 OXOPROPYL] 5 CHLORO 1H INDOLE 2 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HYPERGLYCEMIA; IN VIVO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRICK TEST; PROVOCATION TEST; RAT; RAT STRAIN; WISTAR RAT; ZUCKER RAT;

ANIMALS; ARABINOSE; BLOOD GLUCOSE; ENZYME INHIBITORS; GLUCAGON; GLYCOGEN PHOSPHORYLASE; GLYCOGENOLYSIS; IMINO FURANOSES; INDOLES; MALE; PYRROLIDINES; RATS; RATS, WISTAR; RATS, ZUCKER; SUGAR ALCOHOLS;

RATTUS; RATTUS NORVEGICUS;

EID: 33845992157     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2006.03.005     Document Type: Article

References (16)

1. Apweiler R., and Freund P. Development of glucose intolerance in obese (fa/fa) Zucker rats. Hormone and Metabolic Research 25 (1993) 521-524
2. Bailey C.J., and Flatt P.R. Insulin and glucagon during pentobarbitone anaesthesia. Diabetes and Metabolism (Paris) 6 (1980) 91-95
3. Busse G.D., Freeman K.B., and Riley A.L. The interaction of sex and route of drug administration in cocaine-induced conditioned taste aversions. Pharmacology, Biochemistry and Behavior 81 (2005) 814-820
4. Cardoso A.R., Carvalho C.R.O., Velloso L.A., Brenelli S.L., Saad M.J.A., and Carvalheira J.B.C. Effect of thiopental, pentobarbital and diethyl ether on early steps in insulin action in liver and muscle of the intact rat. Life Sciences 76 (2005) 2287-2297
5. Diraison F., Large V., Brunengraber H., and Beylot M. Non-invasive tracing of liver intermediary metabolism in normal subjects and in moderately hyperglycaemic NIDDM subjects. Evidence against increased gluconeogenesis and hepatic fatty acid oxidation in NIDDM. Diabetologia 41 2 (1998) 212-220
6. Ercan-Fang N., Taylor M.R., Treadway J.L., Levy C.B., Genereux P.E., Gibbs E.M., et al. Endogenous effectors of human liver glycogen phosphorlyase modulate effects of indole site inhibitors. American Journal of Endocrinology and Metabolism 289 (2005) E366-E372
7. Fosgerau K., Westergaard N., Quistorff B., Grunnet N., Kristiansen M., and Lundgren K. Kinetic and functional characterisation of 1,4-Dideoxy-1,4-immuno-d-arbinitol: A potent inhibitor of glycogen Phosphorylase with anti-hyperglyceamic effect in ob/ob mice. Archives of Biochemistry and Biophysics 380 (2000) 274-284
8. Hoover D.J., Lefkowitz-Snow S., Burgess-Henry JL., Martin WH., Armento S.J., Stock I.A., et al. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. Journal of Medicinal Chemistry 41 (1998) 2934-2938
9. Kazumi T., Vranic M., Bar-On H., and Steiner G. Portal v peripheral hyperinsulinemia and very low density lipoprotein triglyceride kinetics. Metabolism 35 11 (1986) 1024-1028
10. Lu Z., Bohn J., Bergeron R., Deng Q., Ellsworth K.P., Geissler W.M., et al. A new class of glycogen phosphorylase inhibitor. Bioorganic and Medicinal Chemistry Letters 13 (2003) 4125-4128
11. Mackay P., Ynddal L., Andersen J.V., and McCormack J.G. Pharmacokinetic and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen Phosphorylase, 1,4-dideoxy-1,4-imino-d-arabinitol, in glucagon challenged rats and dogs and in diabetic ob/ob mice. Diabetes, Obesity and Metabolism 5 (2003) 397-407
12. Martin W.H., Hoover D.J., Armento S.J., Stock I.A., McPherson R.K., Danley D.E., et al. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 1776-1781
13. Newgard C.B., Hwang P.K., and Fletterick R.J. The family of glycogen phosphorylases: Structure and function. Critical Reviews in Biochemistry and Molecular Biology 24 (1989) 69-99
14. Ogawa A.K., Willoughby C.A., Bergeron R., Ellsworth K.P., Geissler W.M., Myers R.W., et al. Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase. Bioorganic and Medicinal Chemistry Letters 13 (2003) 3405-3408
15. Pham D., Jeng A.Y., Plante S., Escher E., and Battistini B. Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery. Canadian Journal of Physiology and Pharmacology 80 5 (2002) 450-457
16. Treadway J.L., Mendys P., and Hoover D.J. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opinion on Investigational Drugs 10 (2001) 439-454